Clinical Observation on Efficacy of Irbesartan Combined with Atorvastatin in Treatment of Hyper-tension Complicated with Paroxysmal Atrial Fibrillation

Bin WANG

DOI: https://doi.org/10.3969/j.issn.1006-2084.2015.21.045

2015-01-01

Abstract:Objective To observe and explore clinical efficacy of irbesartan combined with atorvastatin in treatment of hypertension complicated with paroxysmal atrial fibrillation ( PAF) based on amiodarone for sinus rhythm restoration.Methods A total of 126 cases with hypertension complicated with PAF admitted to Shanghai Jiaotong University School of Medicine Affiliated Xinhua Hospital from Jan .2013 to Jun.2014 were enrolled in the study and were randomized into study group(69 cases) and control group(57 cases) accord-ing to computer generated random number,and all patients got sinus rhythm restoration by amiodaronein in 24 h, while the control group was given oral irbesartan to reduce blood pressure,one tablet per time,one time per day;based on which the study group was added with atorvastatin(2 tablets per day) for 12 weeks.After completion of treatment schedule,the blood pressure and ultrasonic cardiogram indexes were measured,and clinical efficacy and PAF recurrence rate of the two groups were noted and compared .Results After 12 weeks of treatment,blood pressure values of the two groups decreased significantly compared with before treatment,SBP and DBP value of the study group after treatment were both significantly lower than the control group[(128 ±8) mmHg vs (132 ±8) mmHg;(86 ±6) mmHg vs (89 ±7)mmHg](P<0.01).The left ventricular end diastolic diameter ( LVDD ) , left atrial end systolic diameter ( LAD ) , left ventricular mass index (LVMI)of both groups decreased than before treatment,while left ventricular ejection fraction(LVEF) increased than before treatment;after treatment,LVDD,LAD,LVMI values of the study group were signifi-cantly lower than the control group [ ( 48 ±3 ) mm vs ( 49 ±3 ) mm;( 37.0 ±1.3 ) mm vs ( 37.6 ± 1.8) mm;(138 ±5)g/m2 vs (141 ±6) g/m2],LVEF value was significantly higher than the control group [(56 ±6)%vs (54 ±5)%] (P<0.01).After 12 weeks of treatment efficacy of the study group was better than the control group,the recurrence rate was significantly lower than the control group[24.6%(17/69) vs 42.1%(24/57)],the difference was statistically significant(P<0.05).Conclusion Irbesartan combined with atorvastatin in treatment of hypertension patients with PAF can significantly improve cardiac remodeling and function, reduce blood pressure and PAF recurrence, and prevent transition to persistent or permanent PAF.